Akums Q2 FY27 consolidated revenue Rs 1,342.39 cr; PAT Rs 114.56 cr (YoY +168.3%)
Akums Drugs and Pharmaceuticals Ltd reported consolidated revenue of Rs 1,342.39 cr and PAT of Rs 114.56 cr for Q2 FY27, up from Rs 1,017.53 cr and Rs 42.70 cr a year earlier.
Key takeaways
- Revenue from operations Rs 1,342.39 cr vs Rs 1,017.53 cr a year earlier
- Total income Rs 1,371.29 cr vs Rs 1,049.90 cr in the corresponding quarter
- Total expenses Rs 1,216.55 cr vs Rs 984.22 cr in the year-ago quarter
- PBT Rs 154.74 cr vs Rs 65.67 cr in the corresponding prior period
- PAT Rs 114.56 cr vs Rs 42.70 cr; EPS Rs 7.37 vs Rs 2.66
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 1,342.39 cr | Rs 1,017.53 cr | +31.9% |
| PAT | Rs 114.56 cr | Rs 42.70 cr | +168.3% |
| EPS | Rs 7.37 | Rs 2.66 | +177.1% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 8.53% of revenue, up 433 bps from 4.20%.
- Revenue rose 31.9% while total expenses rose 23.6%.
- Cost of materials accounted for Rs 166.83 cr of the Rs 232.33 cr rise in total expenses (71%).
- Cost of materials took 53.6% of revenue, against 54.3% a year earlier.
• Revenue from operations (consolidated): Rs 1,342.39 cr (Q2 FY26: Rs 1,017.53 cr)
• Other income (consolidated): Rs 28.91 cr (Q2 FY26: Rs 32.36 cr)
• Total income (consolidated): Rs 1,371.29 cr (Q2 FY26: Rs 1,049.90 cr)
• Total expenses (consolidated): Rs 1,216.55 cr (Q2 FY26: Rs 984.22 cr)
• Cost of materials consumed (consolidated): Rs 719.46 cr (Q2 FY26: Rs 552.63 cr)
• Purchases of stock-in-trade (consolidated): Rs 50.52 cr (Q2 FY26: Rs 56.71 cr)
• Changes in inventories (consolidated): Rs (3.26) cr (Q2 FY26: Rs (16.77) cr)
• Employee benefits expense (consolidated): Rs 224.27 cr (Q2 FY26: Rs 189.27 cr)
• Finance costs (consolidated): Rs 25.68 cr (Q2 FY26: Rs 23.30 cr)
• Depreciation and amortisation expense (consolidated): Rs 43.21 cr (Q2 FY26: Rs 37.86 cr)
• Other expenses (consolidated): Rs 156.68 cr (Q2 FY26: Rs 141.22 cr)
• Profit before tax – PBT (consolidated): Rs 154.74 cr (Q2 FY26: Rs 65.67 cr)
• Tax expense (consolidated): Rs 40.18 cr (Q2 FY26: Rs 22.98 cr)
• Profit after tax – PAT (consolidated): Rs 114.56 cr (Q2 FY26: Rs 42.70 cr)
• Earnings per share – EPS, basic and diluted (consolidated): Rs 7.37 (Q2 FY26: Rs 2.66)
According to the statement of unaudited consolidated financial results for the quarter and six months period ended 30 September 2026, Akums Drugs and Pharmaceuticals Ltd reported a rise in revenue from operations to Rs 1,342.39 cr for the quarter ended 30 September 2026, compared with Rs 1,017.53 cr in the corresponding quarter ended 30 September 2025. Total income increased to Rs 1,371.29 cr from Rs 1,049.90 cr over the same period.
On the cost side, cost of materials consumed rose to Rs 719.46 cr from Rs 552.63 cr a year earlier. Employee benefits expense increased to Rs 224.27 cr from Rs 189.27 cr, while finance costs moved up to Rs 25.68 cr from Rs 23.30 cr. Depreciation and amortisation expense was Rs 43.21 cr versus Rs 37.86 cr in the year-ago quarter. Other expenses were Rs 156.68 cr compared with Rs 141.22 cr in the corresponding prior period.
Total expenses for the quarter stood at Rs 1,216.55 cr, up from Rs 984.22 cr in the same quarter last year. Profit before tax increased to Rs 154.74 cr from Rs 65.67 cr. Tax expense for the quarter was Rs 40.18 cr, compared with Rs 22.98 cr in the corresponding quarter of the previous year. Profit after tax accordingly rose to Rs 114.56 cr from Rs 42.70 cr. Basic and diluted earnings per share for the quarter were reported at Rs 7.37, compared with Rs 2.66 in the year-ago quarter, as per the statement of financial results.
Track Akums Drugs and Pharmaceuticals Ltd
Cruxal reads every Akums Drugs and Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
